“ReceptivaDx Demonstrates Successful Treatment Outcomes for Improved Live Birth Rates and Reduced Miscarriage Rates” – Associated Press News

The Associated Press (AP News) recently posted on their website about a new pivotal study involving ReceptivaDx. The study showed the treatment outcomes of patients that tested positive for the BCL6 marker after taking the ReceptivaDx test against a control group.

For patients that tested positive for BCL6, treatment results showed a significant increase in clinical pregnancy rate as well as live birth rate. The miscarriage rate also had a significant decrease among patients who tested positive for BCL6.

The study gives thousands of women with unexplained infertility new hope and a new pathway to success, potentially saving thousands of dollars on IVF cycles by identifying patients in advance with low likelihood of IVF success if left untreated. Click here to read more.

Bruce Lessey, M.D., Ph.D. – Scientific Advisor
Lessey’s Corner

The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.

Copyright © 2020 ReceptivaDx™ | All Rights Reserved